Press Releases

4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer Testing

Firefighter #CheckYourFoodTube Precancer Testing Event organized by Mass General Brigham physicians and Boston Firefighters Local 718 IAFF

NEW YORK, June 12, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that the 4,000th firefighter has undergone esophageal precancer testing using Lucid's EsoGuard® Esophageal DNA test as part of a #CheckYourFoodTube Precancer Testing Event. In partnership with physicians from Mass General Brigham, Boston's Local 718 International Association of Fire Fighters (IAFF) hosted its first #CheckYourFoodTube event to ensure its at-risk firefighters could be tested for esophageal precancer. This milestone coincided with Esophageal Cancer Awareness Month and highlighted the proactive steps being taken by the broader firefighter community to address the elevated risk of cancer in firefighters.

"Early detection and preventative screenings are paramount in ensuring the health and safety of everyone, but especially firefighters," said Sam Dillon, Boston Firefighters Local 718 IAFF President. "There is a startling number of firefighters being diagnosed with and dying from esophageal cancer, and the EsoGuard test from Lucid Diagnostics is able to detect precancer signals and allow firefighters like me to go through treatment before actually developing cancer. I strongly encourage all firefighters to take advantage of the #CheckYourFoodTube esophageal precancer screening events, as I did."

 "This was our 105th #CheckYourFoodTube event and represents an important milestone for our EsoGuard commercial efforts," added Shaun O'Neil, Lucid's President and Chief Operating Officer.  "We continue to build out a robust pipeline of these events which have been a key component of our overall strategy to drive test volume. We are grateful for the opportunity to help firefighters like Sam Dillon and other members of Boston Firefighters Local 718 identify esophageal precancer before it becomes a lethal reality for them. We would like to thank Kumar Krishnan, M.D. and Alexandra Maltby of Mass General Brigham for facilitating this #CheckYourFoodTube event, and UpScriptHealth for powering telemedicine consultations for this and other events."

Firefighters have a 62% increased risk of developing esophageal cancer, and a 39% increased risk of dying from the same, according to the Firefighter Cancer Support Group. It is estimated that there will be 22,370 new cases of esophageal cancer in 2024, and that 16,130 people will die this year from this disease, according to the American Cancer Society.

To learn more about hosting a #CheckYourFoodTube Precancer Testing Event, please visit

About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device - the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.

For more information, please visit and for more information about its parent company PAVmed, please visit

Forward-Looking Statements
This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid Diagnostics' management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid Diagnostics' common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid Diagnostics' products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid Diagnostics' clinical and preclinical studies; whether and when Lucid Diagnostics' products are cleared by regulatory authorities; market acceptance of Lucid Diagnostics' products once cleared and commercialized; Lucid Diagnostics' ability to raise additional funding as needed; and other competitive developments. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid Diagnostics' control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid Diagnostics' future operations, see Part I, Item 1A, "Risk Factors," in Lucid Diagnostics' most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report.  Lucid Diagnostics disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.


SOURCE Lucid Diagnostics

For further information: Investor and Media: Matt Riley, PAVmed and Lucid Diagnostics, 610.348.8926,